



**Byotrol  
Plc**

**(“Byotrol” or the  
“Company”)**

**FINAL RESULTS  
FOR THE YEAR ENDED 31 MARCH 2016**

**POSTING OF ANNUAL REPORT AND  
ACCOUNTS AND NOTICE OF AGM**

Byotrol plc, the specialist anti-microbial technology company, is pleased to announce its final results for the 12 months ended 31 March 2016.

We last updated the market in early July; we are pleased to confirm that our final, audited results are in line with that update. Highlights of the year include:

- EBITDA loss before exceptionals of £449k versus £526k in the previous year
- Sharply narrowed loss after tax of £532k (after all exceptionals and tax credits) versus a loss of £749k the previous year
- Cash and cash equivalents of over £1mn, compared to £287k in the prior year
- Continued moves to higher margin transactions, especially by way of licensing and development deals, including with KYORIN Pharmaceutical Co., Ltd (hand sanitisers in Japan), Rentokil Initial plc (hand sanitisers in UK washrooms) and Beaphar NA (surface care products for pet environments) in continental Europe
- Further and expanded agreement to develop and commercialise long-lasting biocidal products for hard surfaces with Solvay Novacare, a world leader in specialty polymers and surfactants and a global business unit of the international chemical group Solvay SA (“Solvay”).

We also confirm continued progress in the technical tests required for formal Environmental Protection Agency (EPA) approval of our surface sanitising products in the US, with an expected registration filing date in early December 2016.

Annual Report & Accounts for the year ended 31 March 2016 have today been posted to shareholders together with the Notice of Annual General Meeting, which will be held at 10am on 22 September 2016 at the offices of finnCap at 60 Broad Street, London EC2M 1JJ.

An electronic copy of the Annual Report and Accounts is also available from the Company’s website: [www.byotrol.co.uk](http://www.byotrol.co.uk).

**Outlook**

Trading for the current year to 31 March 2017 is proceeding to plan, with continued emphasis on higher margin contracts and customers.

As previously notified to shareholders, under the terms of the agreement with Solvay, Solvay will be making substantial payments to the Company. All of those payments are fully committed and will be made in the second half of the current financial year.

**David Traynor, Chief Executive of Byotrol plc comments:**

“We are now showing progress in turning our low-margin, product sales business into a higher margin technology company. We are very confident about our future.”

**Enquiries:**

Byotrol plc  
David Traynor – Chief Executive

01925 742 000

finnCap Ltd  
(Nominated Adviser & Broker)  
Geoff Nash/Carl Holmes/James Thompson - Corporate Finance

020 7220 0500

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

**Notes to Editors:**



Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of residual antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.

Our patented suite of technologies deliver powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens

Founded in 2005, the Company has developed the technology that creates easier, safer and cleaner lives

For more information, please go to [www.byotrol.co.uk](http://www.byotrol.co.uk)